JEIL PHARMA HOLDINGS INC. (002620) Price & Analysis

― Followers

002620 Stock Chart & Stats

₩6930.00

₩0.00(0.00%)

Jul 29, 2026

―

Day’s Range― - ―

52-Week Range₩6,050.00 - ₩9,850.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)14.41K

Market Cap

₩106.38B

Enterprise ValueN/A

Total Cash (Recent Filing)₩83.36B

Total Debt (Recent Filing)₩168.67B

Price to Earnings (P/E)7.9

Beta0.17

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)875.74

Shares Outstanding15,973,355

10 Day Avg. Volume14,200

30 Day Avg. Volume14,414

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)0.40

Price to Sales (P/S)0.20

P/FCF Ratio-16.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

002620 FAQ

What was JEIL PHARMA HOLDINGS INC.’s price range in the past 12 months?

JEIL PHARMA HOLDINGS INC. lowest stock price was ₩6050.00 and its highest was ₩9850.00 in the past 12 months.

What is JEIL PHARMA HOLDINGS INC.’s market cap?

JEIL PHARMA HOLDINGS INC.’s market cap is ₩106.38B.

When is JEIL PHARMA HOLDINGS INC.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were JEIL PHARMA HOLDINGS INC.’s earnings last quarter?

JEIL PHARMA HOLDINGS INC. released its earnings results on May 15, 2026. The company reported ₩71.833 earnings per share for the quarter, beating the consensus estimate of N/A by ₩71.833.

Is JEIL PHARMA HOLDINGS INC. overvalued?

According to Wall Street analysts JEIL PHARMA HOLDINGS INC.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does JEIL PHARMA HOLDINGS INC. pay dividends?

JEIL PHARMA HOLDINGS INC. does not currently pay dividends.

What is JEIL PHARMA HOLDINGS INC.’s EPS estimate?

JEIL PHARMA HOLDINGS INC.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does JEIL PHARMA HOLDINGS INC. have?

JEIL PHARMA HOLDINGS INC. has 15,973,355 shares outstanding.

What happened to JEIL PHARMA HOLDINGS INC.’s price movement after its last earnings report?

JEIL PHARMA HOLDINGS INC. reported an EPS of ₩71.833 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.922%.

Which hedge fund is a major shareholder of JEIL PHARMA HOLDINGS INC.?

Currently, no hedge funds are holding shares in KR:002620

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

JEIL PHARMA HOLDINGS INC.

Jeil Pharma Holdings Inc. is a South Korean pharmaceutical enterprise focused on the production and sale of active pharmaceutical ingredients (APIs), incrementally modified drugs (IMDs), and generic pharmaceuticals. The company's comprehensive API portfolio encompasses a variety of therapeutic areas, including antimicrobials, gastrointestinal remedies, cardiovascular medications, neuropsychiatric treatments, oncology drugs, endocrinology products, urology solutions, antivirals, and antihistamines, in addition to transdermal patch formulations. Furthermore, Jeil Pharma Holdings offers a broad selection of finished dosage forms addressing conditions such as bacterial, fungal, and viral infections; cardiovascular and endocrine disorders; neurological and gastrointestinal ailments; urological and oncological diseases. Its extensive range also features antihistamines, rheumatology, respiratory, otolaryngological, hepatic, and purgative agents. With a global presence, Jeil Pharma Holdings Inc. exports its products to approximately 40 countries, spanning regions like Southeast Asia, Central and South America, and Africa. Founded in 1959, the company's headquarters are situated in Seoul, South Korea.